Based on the efficacy of T-DXd in HER2-positive breast cancer and evidence from pre-clinical models suggesting a clinical effect in tumours with lower levels of HER2 protein expression, a preliminary study by Modi et al. was the first to show a potential clinical role for T-DXd in HER2-low breast cancer [18]. Here, ERBB2 is linked to breast carcinoma.